PBAC's latest decision on Mirikizumab: Recommended with restriction (2023). Considered for Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to conventional therapy.
Therapy area
Gastroenterology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Clinical remission, clinical response
Key trials
LUCENT-3
Comparator
vedolizumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis undertaken; no ICER calculated by design.